94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1544025
This article is part of the Research Topic Infectious Diseases and Hematology: Diagnosis and Management - Volume II View all 10 articles
Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases
Provisionally accepted
ZHI GUO 1,2*
Zhu Jie 2
Jun Wang 3
Liang Wang 4
Fei-Fei Tang 5
Huiqiang Huang 6 Zhongjun Xia 7
LIQIONG LIU 1
Danyu Wang 1 Nan Zhong 1
Huanhuan Zhou 1 Zhaogui Zhou 1
Dai Wei 1
Xiaojun Xu 8
Hao Zhou 9 Lijuan Deng 10 Jingye Meng 11 Zhiqiang Sun 12
Liang Shao 13
Yu J. Cao 14 Yansong Liu 15 Rong Qu 16 Guowei Li 17
Peng Chen 18 Hongyan Zhang 19
Jing Liang 20
YuHua Li 21 Jiajun Liu 22
Zishan Xu 23 Song Song 23
Xiaochen Xiang 2
Qingming Wu 2
Qiang Wang 2*- 1 Department of Hematology, The sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
- 2 School of Medicine, Wuhan University of Science and Technology, Wuhan, Hebei Province, China
- 3 Department of Hematology, Shenzhen Hospital, The University of Hong Kong, Shenzhen, Guangdong Province, China
- 4 Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- 5 Peking University People's Hospital, Beijing, Beijing Municipality, China
- 6 Department of Medical Oncology, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong Province, China
- 7 Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong Province, China
- 8 Department of Hematology, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong Province, China
- 9 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
- 10 Key Laboratory of Carcinogenesis and Translational Research, Beijing Cancer Hospital, Peking University, Beijing, Beijing Municipality, China
- 11 Third People's Hospital,Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
- 12 Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong Province, China
- 13 Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China
- 14 Shenzhen Graduate School, Peking University, Shenzhen, Guangdong, China
- 15 Department of Critical Care Medicine, The 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
- 16 Huizhou Central People's Hospital, Huizhou, Guangdong Province, China
- 17 Department of Hematology,Huizhou central people hospital, Huizhou, Guangdong Province, China
- 18 Department of Hematology, Fifth Medical Center of the PLA General Hospital, Beijing, Beijing Municipality, China
- 19 Department of Oncology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
- 20 Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
- 21 Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
- 22 Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
- 23 Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
Intravenous immunoglobulin（IVIG), first developed for the treatment of patients with antibody deficiencies, is now widely used in clinical practice, especially in hematological and immune system diseases, and its application in hematological oncology chemotherapy, cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) is becoming more and more common. The Chinese Collaborative Group for Infection Immunology and Microecology Research Translation Collaborative Group organized relevant experts to discuss and propose the“Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases”, which was formulated based on the progress of research on the application of IVIG in blood diseases, and provides a basis for the standardization of the use of IVIG in hematologic disorders.
Keywords: IVIG1, clinical application2, hematologic disorders3, chimeric antigen receptor T-Cell4, hematopoietic stem cell transplant (HSCT)5, expert consensus6
Received: 12 Dec 2024; Accepted: 10 Mar 2025.
Copyright: © 2025 GUO, Jie, Wang, Wang, Tang, Huang, Xia, LIU, Wang, Zhong, Zhou, Zhou, Wei, Xu, Zhou, Deng, Meng, Sun, Shao, Cao, Liu, Qu, Li, Chen, Zhang, Liang, Li, Liu, Xu, Song, Xiang, Wu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
ZHI GUO, Department of Hematology, The sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
Qiang Wang, School of Medicine, Wuhan University of Science and Technology, Wuhan, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.